- Free from Publisher K Rossing, P Jacobsen, L Pietraszek, HH … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 20 patients (17 men and 3 women) with
type 2 diabetes along with hypertension and nephropathy were enrolled in this
double-blind, randomized, two-period, crossover trial of 8 weeks of ... Cited by 169 - Related articles - BL Direct - All 6 versions
K ROSSING, KJ SCHJOEDT, BR JENSEN, F … - Kidney international, 2005 - nature.com This double-masked randomized crossover trial included 52 (41 males)
hypertensive type 2 diabetic patients with microalbuminuria on ongoing
antihypertensive medication. At inclusion, previous antihypertensive ... Cited by 128 - Related articles - BL Direct - All 3 versions
- ►annals.org R Kunz, C Friedrich, M Wolbers, JFE Mann - Annals of Internal Medicine, 2007 - Am Coll Physicians This position paper concerns improving health care in the United States. Unlike
previous highly focused policy papers by the American College of Physicians,
this article takes a comprehensive approach to improving access, quality, ... Cited by 118 - Related articles - BL Direct - All 6 versions
- ►asnjournals.org RE Schmieder, AU Klingbeil, EH Fleischmann, … - Journal of the American Society of Nephrology, 2005 - Am Soc Nephrol Proteinuria indicates future renal and cardiovascular morbidity, and,
conversely, its reduction is associated with improved outcome. In a randomized,
double-blind trial with parallel group design, the antiproteinuric effect ... Cited by 77 - Related articles - BL Direct - All 6 versions
AJ Weinberg, DH Zappe, M Ashton, MS … - Am J Nephrol, 2004 - content.karger.com Background: The progression of renal disease is ameliorated by drugs that
inhibit the renin-angiotensin system (RAS). The doses used to slow the
progression of renal disease may not completely suppress the RAS for 24 h ... Cited by 38 - Related articles - BL Direct - All 6 versions
P Aranda, J Segura, LM Ruilope, FJ Aranda, … - American Journal of Kidney Diseases, 2005 - Elsevier Background: This report describes an open randomized study intended to evaluate
the long-term renoprotective effects of “standard” (80 mg once daily) versus
“high” (80 mg twice daily) doses of telmisartan in hypertensive ... Cited by 33 - Related articles - All 10 versions
- ►oxfordjournals.org JH Song, SH Cha, HJ Lee, SW Lee, GH Park, … - Nephrology Dialysis Transplantation, 2006 - ERA-EDTA Results. Subjects consisted of 10 female and 11 male patients with a mean age of
49±8 years and duration of diabetes ranging from 4 to 13 years. At baseline,
24-h blood pressures (BPs) were 133±6/81±7 mmHg, Ccr 40.6±4.1 ... Cited by 32 - Related articles - BL Direct - All 8 versions
P Jacobsen, K Rossing, HH Parving - Current opinion in nephrology and hypertension, 2004 - journals.lww.com Purpose of review Antihypertensive treatment has improved renal prognosis and
survival in diabetic nephropathy. The present review summarizes the current
status of blockade of the renin– angiotensin system in diabetic ... Cited by 31 - Related articles - BL Direct - All 7 versions
- ►asnjournals.org JF Navarro, C Mora, M Muros, J Garcia - Journal of the American Society of Nephrology, 2005 - Am Soc Nephrol Despite the beneficial effects of blockade of the renin-angiotensin system in
diabetic nephropathy (DN), albuminuria and progression of renal disease are not
completely halted by these agents. Therefore, it is necessary to explore ... Cited by 24 - Related articles - BL Direct - All 7 versions
MS Weinberg, N Kaperonis, GL Bakris - Current Hypertension Reports, 2003 - Springer Introduction Diabetic nephropathy is the leading cause of end-stage renal
disease in the United States [1]. Clinical practice guidelines recommend
angiotensin-converting enzyme (ACE) inhibitors in both hypertensive and ... Cited by 22 - Related articles - BL Direct - All 3 versions
